Figure 10From: Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesisCooperative disruption of signaling network downstream of mutated KRAS. Schematic view of KRAS/PAK1/Crk signaling pathway is demonstrated. Partial inhibition of KRAS signaling output by tolerable dose of prenylation inhibitors (i.e., FTI + GGTI) in addition to inhibition of a prominent KRAS effector (i.e., PAK1) result in dramatic anti-tumor effects. FTI: farnesyltransferase inhibitor, GGTI: geranylgeranyltransferase inhibitor, PAK1I: p21 associated kinase 1 inhibitor.Back to article page